Optiray 300
peripheral arteriography, venography, aortography + 8 more
Treatment
1 Active Study for Optiray 300
Treatment for
peripheral arteriography
What is Optiray 300
Ioversol
The Generic name of this drug
Treatment Summary
Ioversol is a special type of dye made from iodine and other substances that allow it to dissolve in water. It is used in medical imaging tests to make different parts of the body stand out clearly on an x-ray or other scan.
Optiray 160
is the brand name
Optiray 300 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Optiray 160
Ioversol
2007
5
Effectiveness
How Optiray 300 Affects Patients
Ioversol is a contrast agent that is used to improve imaging results. After it is injected, its effects are seen almost immediately, usually 15-120 seconds after injection. The time it takes for maximum contrast enhancement may vary depending on what organ is being imaged, and can take up to one hour. For angiographies, maximum contrast enhancement is seen almost immediately. In patients with normal renal function, the calyces and pelves will be visible within 1-3 minutes, and optimal contrast will be visible within 5-15 minutes.
How Optiray 300 works in the body
Ioversol is a special kind of contrast agent used for imaging procedures. When injected into the bloodstream, it causes the vessels to show up clearly on scans. In cases where the blood-brain barrier has been broken, ioversol can also move into the interstitial space and help enhance the imaging. It helps make the images clearer, by increasing the amount of iodine in the dose.
When to interrupt dosage
The preferred measure of Optiray 300 is contingent upon the indicated ailment, including venography, ventriculography and intravenous excretory urography. The amount of dosage fluctuates according to the procedure of administration provided in the table below.
Condition
Dosage
Administration
peripheral arteriography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
venography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
aortography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
Arteriography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
left ventriculography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
Arteriography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
computerized tomography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
angiogram
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
coronary arteriography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
intravenous excretory urography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
Renal Arteriography
68.0 %, , 74.0 %, 51.0 %, 64.0 %, 34.0 %, 509.0 mg/mL, 636.0 mg/mL, 741.0 mg/mL, 678.0 mg/mL, 339.0 mg/mL, 240.0 mg/mL
Solution - Intravascular, , Intravascular, Solution, Intravascular; Subarachnoid, Solution - Intravascular; Subarachnoid, Intravenous, Solution - Intravenous, Intra-arterial; Intravenous, Injection - Intra-arterial; Intravenous, Injection, Liquid - Intravascular, Liquid, Injection - Intravascular
Warnings
Optiray 300 Contraindications
Condition
Risk Level
Notes
Hyperthyroidism
Do Not Combine
There are 20 known major drug interactions with Optiray 300.
Common Optiray 300 Drug Interactions
Drug Name
Risk Level
Description
Acrivastine
Minor
Ioversol may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Ioversol may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Almasilate
Minor
Ioversol may decrease the excretion rate of Almasilate which could result in a higher serum level.
Antihemophilic factor (recombinant), PEGylated
Minor
Ioversol may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antithrombin III human
Minor
Ioversol may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Optiray 300 Toxicity & Overdose Risk
Taking too much ioversol can cause life-threatening damage to the heart, lungs, and other organs. Immediate medical attention should be sought and supportive care should be administered. Ioversol has not been found to have any cancer-causing properties, and it is not known to have any mutagenic or fertility-altering effects. The toxic dose in mice and rats is 17g/kg and 15g/kg, respectively. Tests on pregnant rats and rabbits showed no adverse effects on the embryos or fetuses, but there were some signs of toxicity in the mothers. Additionally, serious complications can occur if the drug is
Optiray 300 Novel Uses: Which Conditions Have a Clinical Trial Featuring Optiray 300?
A single active trial is currently exploring the potential of Optiray 300 to provide venography, arteriography and computerized tomography for treatment of various conditions.
Condition
Clinical Trials
Trial Phases
intravenous excretory urography
0 Actively Recruiting
aortography
0 Actively Recruiting
Arteriography
0 Actively Recruiting
Arteriography
0 Actively Recruiting
Renal Arteriography
0 Actively Recruiting
venography
0 Actively Recruiting
peripheral arteriography
0 Actively Recruiting
coronary arteriography
0 Actively Recruiting
computerized tomography
1 Actively Recruiting
Phase 2
angiogram
0 Actively Recruiting
left ventriculography
0 Actively Recruiting
Patient Q&A Section about optiray 300
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is optiray 300 used for?
"Optiray Injection is a medicine that is injected into the body to help with diagnostic imaging tests, such as CT scans and x-rays. It can be used alone or with other medications."
Answered by AI
What kind of contrast is optiray?
"Optiray 350 contains iodine, which helps X-rays better penetrate the body and produce clearer images. This is especially helpful for examining blood vessels, organs, and other tissues that aren't bony."
Answered by AI
Does optiray have iodine?
"The Optiray 240 solution contains 24% organically bound iodine and has a pH that has been adjusted to fall between 6.0 and 7.4. The solution has been sterilized through autoclaving and does not contain any preservatives."
Answered by AI
Can you drink optiray 300?
"Optiray 300 is an infusion given into a vein or artery. A healthcare provider will give you this injection. It's important to drink extra fluids before and after your radiologic test since Optiray 300 can cause dehydration, which can lead to dangerous effects on your kidneys."
Answered by AI